For fifteen years the honest answer to “is there a GLP-1 pill for weight loss?” was no. There was an oral semaglutide tablet — Rybelsus — but it was approved for type 2 diabetes, at doses whose weight effect was modest and inconsistent. On 22 December 2025 that changed: the FDA approved the Wegovy pill, oral semaglutide at 25 mg once daily, for chronic weight management and for cardiovascular risk reduction in adults with established heart disease and obesity or overweight.[1] It is the first oral GLP-1 receptor agonist approved for weight loss.
The interesting part is not that it works. It is the same molecule as the injection, so of course it works. The interesting part is how much, and the fact that the number you have almost certainly seen is not the trial’s primary result.
What OASIS 4 actually reported
The registration trial was OASIS 4: 71 weeks, double-blind, placebo-controlled, at 22 sites across four countries, enrolling adults without diabetes who had a BMI of 30 or higher, or 27 or higher with at least one weight-related complication. 205 participants were randomized to oral semaglutide 25 mg and 102 to placebo, in a 2:1 ratio.[2]
At week 64, mean body-weight change was −13.6% with oral semaglutide versus −2.2% with placebo — an estimated difference of 11.4 percentage points (95% CI −13.9 to −9.0, P < 0.001).[2] That is the headline result of the trial, and it is the number to plan around.
How it compares with what already existed
- Oral semaglutide 50 mg (OASIS 1, wk 68)-15.1%
the dose that was NOT approved
- Injectable semaglutide 2.4 mg (STEP 1, wk 68)-14.9%
- Oral semaglutide 25 mg (OASIS 4, wk 64)-13.6%
the approved pill
Placebo (OASIS 4): -2.2%
Two things stand out. First, the approved oral dose sits slightly below injectable semaglutide rather than matching it — so “the pill is as good as the shot” is not quite what the evidence says, and none of these drugs were compared directly. Second, and more curiously, the 50 mg oral dose studied in OASIS 1 produced a larger mean loss (−15.1% at week 68)[3] and is not the dose that reached the market. The 25 mg dose is what was approved.
The OASIS program also ran in an East Asian population, with and without type 2 diabetes, in OASIS 2[4] — worth knowing because GLP-1 weight response and tolerability are not uniform across populations, and most of the marquee obesity trials have been run in largely North American and European cohorts.
Why a peptide in a pill needs ten times the dose
Semaglutide is a peptide. Swallowed on its own, it would be digested like any other protein and absorbed essentially not at all. The oral formulation solves this with an absorption enhancer that raises local pH in the stomach and lets a small fraction of the drug cross the gastric mucosa. “A small fraction” is doing real work in that sentence: the injectable is 2.4 mg weekly, the pill is 25 mg daily, and the gap is the cost of going through the stomach.
That mechanism dictates the dosing rules, and the rules are strict. The tablet is taken on an empty stomach after an overnight fast, with no more than a small sip of plain water, and nothing else by mouth — no food, no other medicines, no coffee — for at least 30 minutes afterwards. Follow the FDA label rather than any summary, including this one, and note that the same constraint applies to Rybelsus.
The cardiovascular indication
The approval also covers reducing the risk of major adverse cardiovascular events — cardiovascular death, non-fatal myocardial infarction and non-fatal stroke — in adults with established cardiovascular disease and obesity or overweight.[1] That indication rests on the wider semaglutide evidence base rather than on OASIS 4, which was a weight trial and was not powered for cardiovascular outcomes. The cardiovascular result that matters here is SELECT, run with the injectable, which is worth reading before treating the CV claim as something the pill demonstrated on its own.
What this does and doesn’t change
The genuine change is access, not efficacy. Every previous approved weight-loss GLP-1 required an injection, cold-chain distribution and a device — and for a meaningful number of people, needles are the reason they never started. A tablet made on ordinary pharmaceutical lines removes several of those barriers at once. It is also the second oral entrant in the same year: orforglipron, a non-peptide small molecule with no food or water restrictions at all, was approved for weight management months later. For the trade-off across the whole category, see GLP-1 pill versus injection.
What it does not change is the underlying pharmacology, the side-effect profile, or the fact that this is a long-term treatment for a chronic condition. The adverse events reported in the OASIS program are the familiar GLP-1 ones — nausea, vomiting and diarrhea, mostly early and mostly dose-related — and the prescribing information carries the class boxed warning about thyroid C-cell tumors. If you want the wider picture of how the incretins compare, our evidence matrix grades each of them against the human data.
The honest summary: the first GLP-1 pill for weight loss is real, approved, and slightly less effective on average than the injection it is competing with — and the number you should carry around is −13.6%, not the −16.6% you will see quoted.